Posted by admin on Aug 14th, 2022

SANUWAVE Health (OTCMKTS:SNWV – Get Rating) and Abiomed (NASDAQ:ABMD – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

This table compares SANUWAVE Health and Abiomed’s net margins, return on equity and return on assets.

SANUWAVE Health has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

This is a breakdown of current recommendations and price targets for SANUWAVE Health and Abiomed, as provided by MarketBeat.com.

Abiomed has a consensus target price of $311.25, suggesting a potential upside of 6.02%. Given Abiomed’s higher probable upside, analysts plainly believe Abiomed is more favorable than SANUWAVE Health.

12.9% of SANUWAVE Health shares are owned by institutional investors. Comparatively, 92.0% of Abiomed shares are owned by institutional investors. 9.7% of SANUWAVE Health shares are owned by insiders. Comparatively, 2.5% of Abiomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

This table compares SANUWAVE Health and Abiomed’s top-line revenue, earnings per share and valuation.

Abiomed has higher revenue and earnings than SANUWAVE Health.

Abiomed beats SANUWAVE Health on 9 of the 10 factors compared between the two stocks.

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Receive News & Ratings for SANUWAVE Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SANUWAVE Health and related companies with MarketBeat.com's FREE daily email newsletter.

Financial Comparison: Offerpad Solutions (OPAD) & The Competition

Bed Bath & Beyond Inc. (NASDAQ:BBBY) Receives Average Recommendation of “Reduce” from Analysts